AU2008230722B2 - Systems and methods for a sample fluid collection device - Google Patents

Systems and methods for a sample fluid collection device Download PDF

Info

Publication number: AU2008230722B2
Authority: AU; Australia
Prior art keywords: fluid; sample; collection device; tear; capsule
Prior art date: 2007-03-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2008230722A

Other languages

English (en)

Other versions

AU2008230722A1 (en

Inventor

Graeme John Bullock

Carl Gang Chen

Fred Harry Davis

Adam Ernest Donath

Eric Donsky

Erol Craig Harvey

Andreas Knaack

Sasha Miu

Matthew Daniel Solomon

Benjamin Sullivan

Steve Zmina

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tearlab Res Inc

Original Assignee

Tearlab Research Inc

Tearlab Res Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-28

Filing date

2008-03-28

Publication date

2013-12-12

2007-12-11 Priority claimed from US12/001,243 external-priority patent/US7810380B2/en

2008-03-28 Application filed by Tearlab Research Inc, Tearlab Res Inc filed Critical Tearlab Research Inc

2008-10-02 Publication of AU2008230722A1 publication Critical patent/AU2008230722A1/en

2010-07-22 Assigned to TEARLAB RESEARCH, INC. reassignment TEARLAB RESEARCH, INC. Alteration of Name(s) of Applicant(s) under S113 Assignors: OCUSENSE, INC.

2013-12-12 Application granted granted Critical

2013-12-12 Publication of AU2008230722B2 publication Critical patent/AU2008230722B2/en

2014-03-11 Priority to AU2014201346A priority Critical patent/AU2014201346B2/en

Status Ceased legal-status Critical Current

2028-03-28 Anticipated expiration legal-status Critical

Links

239000012530 fluid Substances 0.000 title claims abstract description 198
238000000034 method Methods 0.000 title description 74
239000000758 substrate Substances 0.000 claims abstract description 109
239000002775 capsule Substances 0.000 claims abstract description 60
230000009471 action Effects 0.000 claims abstract description 20
230000005499 meniscus Effects 0.000 claims description 9
230000000007 visual effect Effects 0.000 claims description 5
239000000523 sample Substances 0.000 description 242
238000012545 processing Methods 0.000 description 58
238000005259 measurement Methods 0.000 description 52
239000000463 material Substances 0.000 description 24
230000008014 freezing Effects 0.000 description 22
238000007710 freezing Methods 0.000 description 22
238000010586 diagram Methods 0.000 description 20
239000011521 glass Substances 0.000 description 16
230000008020 evaporation Effects 0.000 description 14
238000001704 evaporation Methods 0.000 description 14
208000003556 Dry Eye Syndromes Diseases 0.000 description 13
206010013774 Dry eye Diseases 0.000 description 13
230000008859 change Effects 0.000 description 13
230000003287 optical effect Effects 0.000 description 13
230000008569 process Effects 0.000 description 13
230000026683 transduction Effects 0.000 description 13
238000010361 transduction Methods 0.000 description 13
238000012546 transfer Methods 0.000 description 13
238000013528 artificial neural network Methods 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 11
239000004820 Pressure-sensitive adhesive Substances 0.000 description 10
230000007246 mechanism Effects 0.000 description 10
239000012491 analyte Substances 0.000 description 9
238000011088 calibration curve Methods 0.000 description 9
238000010276 construction Methods 0.000 description 9
230000006870 function Effects 0.000 description 9
238000013461 design Methods 0.000 description 8
239000002102 nanobead Substances 0.000 description 8
239000004417 polycarbonate Substances 0.000 description 8
229920000515 polycarbonate Polymers 0.000 description 8
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 7
239000000853 adhesive Substances 0.000 description 7
230000001070 adhesive effect Effects 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
238000004806 packaging method and process Methods 0.000 description 7
239000004065 semiconductor Substances 0.000 description 7
230000002209 hydrophobic effect Effects 0.000 description 6
238000001816 cooling Methods 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
230000011514 reflex Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 4
238000013459 approach Methods 0.000 description 4
210000005224 forefinger Anatomy 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000033001 locomotion Effects 0.000 description 4
238000000691 measurement method Methods 0.000 description 4
238000010606 normalization Methods 0.000 description 4
238000002103 osmometry Methods 0.000 description 4
238000000206 photolithography Methods 0.000 description 4
229920000728 polyester Polymers 0.000 description 4
210000003813 thumb Anatomy 0.000 description 4
238000013519 translation Methods 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000011324 bead Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000000576 coating method Methods 0.000 description 3
210000000795 conjunctiva Anatomy 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
210000000744 eyelid Anatomy 0.000 description 3
210000003811 finger Anatomy 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000011347 resin Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
-1 sweat Substances 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229920002614 Polyether block amide Polymers 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
239000000090 biomarker Substances 0.000 description 2
230000004397 blinking Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
229920001940 conductive polymer Polymers 0.000 description 2
210000004087 cornea Anatomy 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
230000036541 health Effects 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229940099472 immunoglobulin a Drugs 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920001610 polycaprolactone Polymers 0.000 description 2
239000004632 polycaprolactone Substances 0.000 description 2
229920006393 polyether sulfone Polymers 0.000 description 2
229920000139 polyethylene terephthalate Polymers 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
229920002635 polyurethane Polymers 0.000 description 2
239000004814 polyurethane Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
238000005070 sampling Methods 0.000 description 2
238000007789 sealing Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000004381 surface treatment Methods 0.000 description 2
210000004243 sweat Anatomy 0.000 description 2
238000012549 training Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000009736 wetting Methods 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
206010002261 Androgen deficiency Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
102000010445 Lactoferrin Human genes 0.000 description 1
108010063045 Lactoferrin Proteins 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
239000004642 Polyimide Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000004433 Thermoplastic polyurethane Substances 0.000 description 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010047571 Visual impairment Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000004082 amperometric method Methods 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000000607 artificial tear Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
244000078885 bloodborne pathogen Species 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
BRXCDHOLJPJLLT-UHFFFAOYSA-N butane-2-sulfonic acid Chemical compound CCC(C)S(O)(=O)=O BRXCDHOLJPJLLT-UHFFFAOYSA-N 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000005684 electric field Effects 0.000 description 1
210000003560 epithelium corneal Anatomy 0.000 description 1
239000003822 epoxy resin Substances 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
210000003128 head Anatomy 0.000 description 1
229920001480 hydrophilic copolymer Polymers 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
238000002847 impedance measurement Methods 0.000 description 1
238000001566 impedance spectroscopy Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
229940078795 lactoferrin Drugs 0.000 description 1
235000021242 lactoferrin Nutrition 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
230000013011 mating Effects 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
238000001465 metallisation Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000002991 molded plastic Substances 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
238000001020 plasma etching Methods 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
229920000647 polyepoxide Polymers 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229920001721 polyimide Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920000128 polypyrrole Polymers 0.000 description 1
229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
229920002717 polyvinylpyridine Polymers 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000135 prohibitive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000006479 redox reaction Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000565 sealant Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000012358 sourcing Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000013526 supercooled liquid Substances 0.000 description 1
230000003746 surface roughness Effects 0.000 description 1
235000013616 tea Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229920002803 thermoplastic polyurethane Polymers 0.000 description 1
229910052719 titanium Inorganic materials 0.000 description 1
239000010936 titanium Substances 0.000 description 1
MAKDTFFYCIMFQP-UHFFFAOYSA-N titanium tungsten Chemical compound [Ti].[W] MAKDTFFYCIMFQP-UHFFFAOYSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229920000428 triblock copolymer Polymers 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
238000000214 vapour pressure osmometry Methods 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
208000029257 vision disease Diseases 0.000 description 1
230000004304 visual acuity Effects 0.000 description 1
230000004393 visual impairment Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N13/04—Investigating osmotic effects
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/101—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for examining the tear film
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B2010/0067—Tear or lachrymal fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Surgery (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Animal Behavior & Ethology (AREA)
Pathology (AREA)
Public Health (AREA)
Biophysics (AREA)
Chemical & Material Sciences (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)

AU2008230722A 2007-03-28 2008-03-28 Systems and methods for a sample fluid collection device Ceased AU2008230722B2 (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
AU2014201346A AU2014201346B2 (en)	2007-03-28	2014-03-11	Systems and methods for a sample fluid collection device

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US90865407P	2007-03-28	2007-03-28
US60/908,654		2007-03-28
US12/001,243 US7810380B2 (en)	2003-03-25	2007-12-11	Systems and methods for collecting tear film and measuring tear film osmolarity
US12/001,243		2007-12-11
PCT/US2008/058731 WO2008119069A1 (fr)	2007-03-28	2008-03-28	Systèmes et procédés pour un dispositif de collecte de liquide d'échantillon

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2014201346A Division AU2014201346B2 (en)	2007-03-28	2014-03-11	Systems and methods for a sample fluid collection device

Publications (2)

Publication Number	Publication Date
AU2008230722A1 AU2008230722A1 (en)	2008-10-02
AU2008230722B2 true AU2008230722B2 (en)	2013-12-12

Family

ID=50638361

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2008230722A Ceased AU2008230722B2 (en)	2007-03-28	2008-03-28	Systems and methods for a sample fluid collection device

Country Status (4)

Country	Link
EP (1)	EP2130024A4 (fr)
AU (1)	AU2008230722B2 (fr)
CA (1)	CA2682070C (fr)
WO (1)	WO2008119069A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7810380B2 (en)	2003-03-25	2010-10-12	Tearlab Research, Inc.	Systems and methods for collecting tear film and measuring tear film osmolarity
AU2015320685B2 (en)	2014-09-23	2021-01-28	Tearlab Research, Inc.	Systems and methods for integration of microfluidic tear collection and lateral flow analysis of analytes of interest

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060137435A1 (en) *	2002-08-06	2006-06-29	The Regents Of The University Of California	Tear film osmometry
US7133712B2 (en) *	2002-04-05	2006-11-07	Eyelab Group, Llc	Method and apparatus for non-invasive monitoring of blood substances using self-sampled tears

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5143080A (en) *	1988-12-07	1992-09-01	York Kenneth K	In vivo osmometer
US4951683A (en) *	1989-01-19	1990-08-28	Davis Jeffrey P	Device for detecting keratoconjunctivitis sicca
US5221457A (en) *	1991-09-23	1993-06-22	Porton Diagnostics, Inc.	System for analyzing ion levels in fluids
ES2184236T3 (es) *	1997-02-06	2003-04-01	Therasense Inc	Sensor in vitro de analitos de pequeño volumen.
ES2320871T3 (es) *	2002-07-18	2009-05-29	Panasonic Corporation	Aparato de medicion con un biosensor.
US7111502B2 (en) *	2002-08-06	2006-09-26	Ocusense, Inc.	Systems and methods for reducing the effect of corruptive signals during nanoliter osmometry
US20050201895A1 (en) *	2004-03-12	2005-09-15	Eric Donsky	Systems and methods for delivering a sample fluid to a receiving substrate
WO2005089210A2 (fr) *	2004-03-12	2005-09-29	Ocusense, Inc.	Systemes et procedes permettant de collecter et d'analyser des donnees concernant l'osmolarite du film lacrymal

2008
- 2008-03-28 WO PCT/US2008/058731 patent/WO2008119069A1/fr not_active Ceased
- 2008-03-28 CA CA2682070A patent/CA2682070C/fr not_active Expired - Fee Related
- 2008-03-28 AU AU2008230722A patent/AU2008230722B2/en not_active Ceased
- 2008-03-28 EP EP08744661.3A patent/EP2130024A4/fr not_active Withdrawn

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7133712B2 (en) *	2002-04-05	2006-11-07	Eyelab Group, Llc	Method and apparatus for non-invasive monitoring of blood substances using self-sampled tears
US20060137435A1 (en) *	2002-08-06	2006-06-29	The Regents Of The University Of California	Tear film osmometry

Also Published As

Publication number	Publication date
EP2130024A4 (fr)	2014-04-23
WO2008119069A1 (fr)	2008-10-02
AU2008230722A1 (en)	2008-10-02
CA2682070A1 (fr)	2008-10-02
CA2682070C (fr)	2014-02-04
EP2130024A1 (fr)	2009-12-09

Publication	Publication Date	Title
US9335243B2 (en)	2016-05-10	Systems and methods for collecting tear film and measuring tear film osmolarity
US8020433B2 (en)	2011-09-20	Systems and methods for a sample fluid collection device
US7574902B2 (en)	2009-08-18	Tear film osmometry
US9217701B2 (en)	2015-12-22	Biomarker normalization
HK1224379A1 (en)	2017-08-18	Systems and methods for collecting tear film and measuring tear film osmolarity
AU2008230722B2 (en)	2013-12-12	Systems and methods for a sample fluid collection device
AU2014201346B2 (en)	2015-09-03	Systems and methods for a sample fluid collection device
ES2410058T3 (es)	2013-06-28	Normalización de biomarcadores
HK1152113A (en)	2012-02-17	Tear film osmometry

Legal Events

Date	Code	Title	Description
2014-04-10	FGA	Letters patent sealed or granted (standard patent)
2018-10-25	MK14	Patent ceased section 143(a) (annual fees not paid) or expired